Please login to the form below
Adderall
This page shows the latest Adderall news and features for those working in and with pharma, biotech and healthcare.
Shire offloads oncology unit to Servier for $2.4bn
The neuroscience arm includes Shire’s attention-deficit hyperactivity drugs such as Adderall XR (mixed amphetamine salts) and brought in $2.66bn in sales last year.
Latest news
-
Shire separates out neuroscience as it considers its future
Historically dependent on just one ADHD treatment - Adderall -, neuroscience has dwindled in the face of Shire’s rising presence in orphan drugs and last year it accounted for less than a
-
Shire claims FDA approval for slow-cooked ADHD drug
The longer-acting drug - which was first submitted to the FDA back in 2006 but turned down by the regulator - has the same active ingredient as Shire's older drug Adderall ... modest $288m by 2020, mainly because of anticipated payer resistance in the US
-
Shire pitching at adult ADHD product launch in 2017
Adults already receive treatment for ADHD off-label using drugs such as Adderall and Adderall XR - both also based on mixed amphetamine salts - but it is though that a sizeable proportion
-
Shire reaches $56.5m US marketing malpractice settlement
Justice Department agreement covers activities for drugs including Adderall. Irish biopharma company Shire has agreed to pay a multi-million dollar fine to the US Justice Department to settle allegations that ... The allegations included its attention
-
Shire's ADHD drug fails in depression trial
The company has built much of its business on its ADHD products, which also include the now off-patent Adderall, but Shire is now turning its attention to the growing market
More from news
Approximately 3 fully matching, plus 79 partially matching documents found.
Latest Intelligence
-
Challenging perceptions
Meanwhile, the US also has the amphetamine-based class - Shire's historic territory with Adderall and its flagship product Vyvanse.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Shire elects new chair
During that time Shire has grown substantially, although has struggled in recent years with generic competition for big-selling attention deficit-hyperactivity disorder (ADHD) drug Adderall XR and plans to downsize
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
